Skip to content

Iron Sucrose

    Brands

    DEA Class; Rx

    Common Brand Names; Venofer

    • Iron Products

    IV iron supplement and oral phosphate binder
    Used IV for the treatment of iron deficiency anemia in patients with chronic kidney disease and orally for control of serum phosphorus levels in patients with chronic kidney disease on dialysis
    Can cause serious, even fatal, hypersensitivity reactions when administered IV; although less likely to cause hypersensitivity than iron dextran, facilities for cardiopulmonary resuscitation must be available during dosing

    Indicated for the treatment of iron-deficiency anemia in patients with chronic kidney disease.

    Indicated for treatment of iron deficiency anemia associated with chronic kidney disease

    Hypersensitivity

    Anemia not caused by iron deficiency

    Iron overload

    • Hypotension (36%)
    • Muscle cramps (23%)
    • Headache
    • Nausea
    • Dizziness
    • Fatigue
    • Arthralgia
    • Back pain
    • Hypertension
    • Fluid overload
    • Peripheral edema
    • Cough
    • Vomiting
    • Diarrhea
    • Constipation
    • Pruritus

    Risk of hypotension

    Withhold therapy in tissue iron overload

    Hypersensitivity

    • Serious hypersensitivity reactions reported, including anaphylactic-type reactions, some of which have been life-threatening and fatal
    • Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse
    • If hypersensitivity reactions or signs of intolerance occur during administration, stop infusion immediately
    • Monitor patients for signs and symptoms of hypersensitivity during and after administration for at least 30 minutes and until clinically stable following completion of the infusion

    Published studies on intravenous iron sucrose treatment after first trimester of pregnancy not shown adverse maternal or fetal outcomes

    Iron sucrose is present in human milk, and available published reports following exposure to 100-300 mg intravenous iron sucrose have not reported adverse reactions in breastfed infants; there are no data on effects on milk production

    Adults

    500 mg/dose IV has been administered on 2 consecutive days in patients with chronic kidney disease. Up to 3000 mg/day PO has been studied in patients with end stage renal disease.

    Geriatric

    500 mg/dose IV has been administered on 2 consecutive days in patients with chronic kidney disease. Up to 3000 mg/day PO has been studied in patients with end stage renal disease.

    Adolescents

    0.5 mg/kg IV up to a max of 100 mg/dose IV. Safety and efficacy of iron sucrose chewable tablets have not been established.

    Children

    >= 2 years: 0.5 mg/kg IV up to a max of 100 mg/dose IV. Safety and efficacy of iron sucrose chewable tablets have not been established.
    < 2 years: Safety and efficacy have not been established.

    Infants

    Safety and efficacy have not been established.

    Neonates

    Safety and efficacy have not been established.

    Iron sucrose

    injectable solution

    • 20mg (Fe)/mL